Investors Presentation - Q1FY27

August 17, 2026 BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th Floor, Plot No.C/1, G Block, Dalal Street, Fort, Bandra Kurla Complex, Bandra East, Mumbai 400 001. Mumbai 400051. Scrip Code: 524774 Symbol: NGLFINE Dear Sir/Madam, Sub: Investor Presentation – Q1FY 27. Dear Sir/Madam, Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit Investors Presentation – Q1FY 27. The above presentation is also being made available on the Company’s website at www.nglfinechem.com. You are requested to kindly take the information on record. Thanking you, Yours faithfully, For NGL Fine-Chem Limited Shivam Gharat Company Secretary and Compliance Officer M. No.: A56704 Encl: As Above. NGL Fine-Chem Limited I N V E S T O R P R E S E N T A T I O N Q 1 FY 2 7 Disclaimer This investor presentation has been prepared by NGL Fine-Chem Limited and does not constitute a prospectus or placement memorandum or an offer to acquire any securities. This presentation or any other documentation or information (or any part thereof) delivered or supplied should not be deemed to constitute an offer. No representation or warranty, express or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of such information or opinions contained herein. The information contained in this presentation is only current as of its date. Certain statements made in this presentation may not be based on historical information or facts and may be "forward looking statements", including those relating to the general business plans and strategy of NGL Fine-Chem Limited, its future financial condition and growth prospects, future developments in its industry and its competitive and regulatory environment, and statements which contain words or phrases such as 'will', 'expected to', 'horizons of growth', 'strong growth prospects', etc., or similar expressions or variations of such expressions. These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results, opportunities and growth potential to differ materially from those suggested by the forward-looking statements. NGL Fine-Chem Limited may alter, modify or otherwise change in any manner the content of this presentation, without obligation to notify any person of such revision or changes. This presentation cannot be copied and disseminated in any manner. 02 NGL Fine-Chem Limited Inside Pg. No. Pg. No. This Presentation 04 10 Q1FY27 Overview, Highlights Key Strengths and Strategy Pg. No. Historical Financial Performance Q1FY27 Highlights 05 MANAGEMENT COMMENTARY 06 QUARTERLY OPERATIONAL METRICS 07 SUMMARY OF PROFIT AND LOSS STATEMENT 08 SUMMARY OF BALANCE SHEET 09 SUMMARY OF CASH FLOW STATEMENT MANAGEMENT COMMENTARY Dear Shareholders, “Q1FY27 sustained the demand momentum we Against a loss of ₹4.5 crore in Q4FY26, we recorded witnessed in Q4FY26, with volumes remaining a forex gain of ₹2.5 crore in Q1FY27, providing a robust across our product segments and measurable uplift to reported earnings. Investors geographies. The business continues on its recovery should note that these mark-to-market movements trajectory, supported by stable market conditions are inherently volatile and may not recur at the and improved customer off-take. same magnitude in future periods. The quarter reflects healthy operating margins; On the capex front, Phase II remains on schedule however, part of the improvement is attributable to and is expected to be commissioned during the inventory gains arising from price increases during current quarter. Total project cost and scope remain the period. As price realisations normalise, we unchanged, and we are on track to commence Rahul Nachane expect margins to moderate over the coming commercial production from H2FY27 as planned. MANAGING DIRECTOR quarters, which we view as a natural correction and The incremental capacity is expected to support our not indicative of any structural change in the growth plans and enhance our ability to address business. We continue to remain confident about emerging opportunities in both existing and new our medium-term earnings outlook, driven by markets. underlying demand and operating leverage. With a stable market environment, sustained A notable contributor to improved profitability this demand, and our expanded capacity, we believe the quarter was the reversal of mark-to-market forex business is well-positioned to deliver steady, provisions that had weighed on Q4FY26 results. sustainable growth in the medium term.” 05 NGL Fine-Chem Limited Quarterly Operational Metrics SEGMENTAL REVENUE MIX PRODUCT CONCENTRATION PARTICULARS Q1FY26 Q4FY26 Q1FY27 PARTICULARS Q1FY26 Q4FY26 Q1FY27 ANIMAL API 92% 95% 95% TOP 3 PRODUCTS 30% 29% 31% HUMAN API 4% 2% 3% TOP 5 PRODUCTS 42% 44% 48% INTERMEDIATES 3% 1% 1% TOP 10 PRODUCTS 63% 66% 68% FORMULATIONS 1% 1% 0% GEOGRAPHIC MIX CUSTOMER CONCENTRATION PARTICULARS Q1FY26 Q4FY26 Q1FY27 PARTICULARS Q1FY26 Q4FY26 Q1FY27 Asia 32% 43% 40% TOP 3 CUSTOMERS 15% 12% 18% Europe 13% 9% 10% TOP 5 CUSTOMERS 21% 18% 26% India 25% 23% 20% ROW 30% 26% 30% TOP 10 CUSTOMERS 37% 29% 38% USA 1% 0% 0% 06 NGL Fine-Chem Limited Summary of Profit and Loss Statement ₹ IN CRORES PARTICULARS Q1FY26 Q4FY26 Q1FY27 Q-o-Q Y-o-Y REVENUE FROM OPERATIONS 104.19 149.23 139.16 -6.75% 33.57% OTHER INCOME 6.35 2.46 7.43 202.05% 16.91% TOTAL INCOME 110.54 151.69 146.59 -3.36% 32.61% TOTAL OPERATING EXPENSES 93.21 127.82 115.88 -9.35% 24.31% EBITDA 10.97 21.41 23.29 8.76% 112.21% EBITDA MARGIN (%) 10.53% 14.35% 16.73% 239 bps 620 bps FINANCE COST 1.22 1.01 0.99 -2.23% -19.39% DEPRECIATION AND AMORTISATION EXPENSES 4.27 5.05 5.25 4.01% 23.16% PROFIT BEFORE TAX 11.84 17.81 24.48 37.41% 106.74% PROFIT AFTER TAX 9.24 13.49 18.40 36.42% 99.09% 07 NGL Fine-Chem Limited Summary of Balance Sheet ₹ IN CRORES PARTICULARS FY25 FY26 SHAREHOLDERS FUND 282.43 329.23 NON CURRENT LIABILITIES 31.99 66.25 LONG TERM BORROWINGS 25.34 56.40 CURRENT LIABILITIES 118.97 150.01 SHORT TERM BORROWINGS 48.00 52.02 TOTAL EQUITY AND LIABILITIES 433.39 545.50 NON CURRENT ASSETS 198.01 269.11 NET BLOCK 142.12 164.09 CURRENT ASSETS 235.38 276.39 INVENTORIES 51.27 70.28 TRADE RECEIVABLES 82.84 130.88 CASH & BANK BALANCES 4.97 5.11 TOTAL ASSETS 433.39 545.50 08 NGL Fine-Chem Limited Summary of Cash Flow Statement ₹ IN CRORES PARTICULARS FY25 FY26 CASH FLOW FROM OPERATING ACTIVITIES 32.36 43.32 CASH FLOW FROM INVESTING ACTIVITIES (69.68) (70.59) CASH FLOW FROM FINANCING ACTIVITIES 37.46 29.55 NET CASH FLOW 0.14 2.27 CASH AT THE BEGINNING OF YEAR 0.40 0.53 CASH AT THE END OF YEAR 0.53 2.81 09 NGL Fine-Chem Limited Overview, Strengths and Strategy 11 LEADING ANIMAL HEALTH COMPANY 12 LEADERSHIP IN VETERINARY API SEGMENT 13 STATE-OF-THE-ART MANUFACTURING CAPABILITIES 14 STRATEGY FOR NEXT LEG OF GROWTH Leading Animal Health Company COMPREHENSIVE MARKET MANUFACTURING LARGE GLOBAL LONG STANDING PRODUCT LEADERSHIP EXCELLENCE PRESENCE CUSTOMER PORTFOLIO IN VETERINARY API RELATIONSHIPS • 45 APIs (43 Veterinary • Market leadership in • 3 state of the art • Strong presence • ~451 customers APIs, 2 Human APIs), our top products manufacturing across the globe with 1 Intermediates and facilities country-wise • Reliable supplier 11 finished dosage • Growing position in regulatory approvals focused on good forms next 4 – taking market • Strong R&D sale support to all share from other capabilities in • Strong presence in customers • Best quality and players custom synthesis unregulated markets value-driven pricing 11 NGL Fine-Chem Limited Leadership in Veterinary API Segment REVENUE FROM VETERINARY CUSTOMER & PRODUCT API SEGMENT CONCENTRATION Strong controls of processes with 13 95% in-house manufacturing and (₹ IN CRORES) (OF SALES FY26) CAGR backward integrated facilities leading to cost competitiveness FY26 466 CUSTOMER [Showing first 8,000 characters — download PDF for full document]